• XpresSpa Group Inc (NASDAQ: XSPA) has extended its initial million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck. The extension brings the total contract to $5.6 million.

• The COVID-19 biosurveillance program, first launched in September 2021, provided testing for travelers arriving from India at three key U.S. airports, including John F. Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport.

• With the recent expansion, the program now tests passengers entering the U.S. from seven African countries, including passengers making connections through the U.K., France, Germany, and Brazil.

• The expansion includes the addition of Hartsfield-Jackson Atlanta International Airport, bringing the number of testing sites to four.

• Price Action: XSPA shares traded higher by 4.10% at $1.40 on the last check Monday.

See more from Benzinga

• XpresSpa Group Appoints Scott Milford As CEO

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.